selumetinib sulfate
Marketedupdated 2mo agoby AstraZeneca Pharmaceuticals LP
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neurofibromatosis type 1 and neoplasm and 20 investigational indications.
all catalysts(7)
approval · 7
Apr 10, 2020
approval
KOSELUGO (SELUMETINIB SULFATE) — FDA approval
selumetinib sulfate
→
Dec 22, 2021
approval
KOSELUGO (SELUMETINIB SULFATE) — FDA approval
selumetinib sulfate
→
Jan 24, 2024
approval
KOSELUGO (SELUMETINIB SULFATE) — FDA approval
selumetinib sulfate
→
Sep 10, 2025
approval
KOSELUGO (SELUMETINIB SULFATE) — FDA approval
selumetinib sulfate
→
Sep 10, 2025
approval
KOSELUGO (SELUMETINIB) — FDA approval
selumetinib sulfate
→
Nov 19, 2025
approval
KOSELUGO (SELUMETINIB SULFATE) — FDA approval
selumetinib sulfate
→
Nov 19, 2025
approval
KOSELUGO (SELUMETINIB) — FDA approval
selumetinib sulfate
→
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that